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Abstract 35 
Negligible solubility of curcumin in water combined with rapid degradation have 36 
limited its medical applications. In this contribution, eutectic mixture of curcumin with 37 
one of its degradation products (ferulic acid) was encapsulated into long and medium 38 
chain triglycerides oils and stabilised by the non-ionic surfactant polyoxyethylene 39 
oleyl ether Brij® O10 (C18:1E10) and bile acid derivative (sodium deoxycholate).  40 
Thermal and spectroscopic analysis confirmed the presence of curcumin as solid 41 
nanocrystals embedded within the microemulsion droplets.  UV-spectroscopy and 42 
LC-MS studies of formed microemulsions revealed that degradation of curcumin in 43 
water was significantly reduced with more than 83% of curcumin remained intact 44 
after 24 hours. 1H NMR results showed that curcumin remained stable upon heating 45 
in the range between 297K-327 K with no signs of degradation to ferulic acid. The 46 
results showed solubility enhancement of curcumin with a range of 3-5 mg/mL.  NF-47 
κB reporter cell assay revealed low cytotoxicity and three folds stronger anti-48 
inflammatory potential compared to curcumin. Microemulsions remained stable for 49 
over 12 months with extended stability of formulations that contained 50 
curcumin/ferulic acid in glyceryl tricaprate based microemulsions.  Overall these 51 
results suggest novel role for particle engineering via using ferulic acid as stability 52 
and activity enhancer for curcumin through free radicals scavenging mechanism.  53 
 54 
 55 














1. Introduction 70 
Curcumin (CUR) is the most pharmacologically active component in turmeric, which 71 
gives rise to its broad spectrum of clinical applications. It has been shown as 72 
potential treatment for cancer, Alzheimer’s disease and ulcerative colitis [1-3]. A 73 
proposed mechanism of action is CUR’s role in O2 scavenging [4], NF-κB 74 
suppression and downregulation of interleukins and other inflammatory cytokines [5]. 75 
CUR is also known to prevent tumour growth via inhibition of DNA binding to 76 
polycyclic hydrocarbon metabolites [6]. Despite these beneficial properties, CUR has 77 
two major disadvantages, limiting its exploitation as a therapeutic agent. Firstly, CUR 78 
is practically insoluble in aqueous media, hindering its absorption. As a hydrophobic 79 
polyphenol, curcumin is classified based on the biopharmaceutical classification 80 
system (BCS) as a class IV molecule due to its low aqueous solubility and its poor 81 
penetration through the intestinal wall [7-9].  Secondly, CUR degrades rapidly at 82 
physiological conditions, leading to less pharmacologically active metabolites. In 83 
neutral or slightly alkaline conditions, CUR degrades by autoxidation and reaction 84 
with molecular oxygen to form bicyclopentadione [10].  Other minor degradation 85 
products due to alkaline hydrolysis and molecular cleavage are vanillin, ferulic acid 86 
and ferulolymethane [9, 11]. Photodegradation can also occur leading to formation of 87 
vanillic and ferulic acid (FA) [11]. Overall, CUR degrades rapidly at physiological 88 
conditions, leading to approximately 10% remaining after 30 minutes [12]. Low 89 
solubility is also associated with accumulation of CUR in intestinal wall causing 90 
extensive epithelial metabolism [8].    91 
 92 
There have been different attempts to improve CUR solubility that were based on 93 
use of cyclodextrins, solid dispersions and microemulsions [9, 13-15].  Other 94 
examples of previous attempts include solid lipid nanoparticles, transfersomes and 95 
liposomes [16-18].  While the benefits of these approaches have been 96 
demonstrated, the clinical use of CUR remains limited due to chemical degradation 97 
as was previously shown in previous studies [19, 20].  Hence in this study we 98 
present synergistic microemulsion system of triglyceride (oil phase) encapsulating 99 
curcumin-ferulic acid eutectic nanocrystals (Figure 1).  While this eutectic was 100 
reported previously [21], its physiological use remains limited as according to our 101 
experiments this eutectic has negligible solubility in water or phosphate buffer. 102 
Ferulic acid (FA) has been shown to exert similar effects to CUR and in some 103 
studies, it was suggested that some of the anti-inflammatory effects of CUR were 104 
attributed to FA [22]. Recently, it was shown that the adjuvant administration of CUR 105 
and FA was effective in counteracting chemoresistance and cisplatin-induced 106 
ototoxicity [23].  Exploiting CUR/FA eutectic to prevent degradation of CUR has not 107 
been studied hence this will be the focus of this contribution.  Since that the oral 108 
route represents the major route for drug delivery, the aim of this contribution is to 109 
formulate CUR for oral drug delivery.  110 
 111 
We hypothesise that maintaining the eutectic structure as nanocrystals inside the 112 
microemulsion droplets/particle can enhance the stability of encapsulated curcumin 113 
and achieve a synergistic effect.  The use of ferulic acid as a co-former can slow 114 
down CUR degradation by scavenging free radicals that initiate autoxidation.  The 115 
non-ionic surfactant polyoxyethylene oleyl ether Brij® O10 (C18:1E10) and the bile salt 116 
derivative sodium deoxycholate (SD) were used to form the microemulsions.  117 
Analysis of microemulsions formation was performed to find optimum surfactants 118 
system to prepare the microemulsions. It is worth mentioning that the composition of 119 
these microemulsions is novel and has not been reported in the literature. 120 
Triglycerides are naturally occurring lipids and commonly used as excipients [24]. 121 
The oil glyceryl tricaprate is 9 carbons medium chain triglyceride while glyceryl 122 
trioleate is 17 carbons long chain triglyceride with unsaturation at C9.  Apart from the 123 
difference in molecular weight, glyceryl trioleate is liquid at room temperature and 124 
monounsaturated while glycerol tricaprate is a saturated solid oil at room 125 
temperature.   To make comparison clearer we will refer to glyceryl trioleate as the 126 
liquid oil and for glyceryl tricaprate as the solid oil throughout this research paper.  127 
Finally, the impact of the physical state of the oil and microemulsions composition on 128 
degradation of curcumin will be discussed. 129 
 130 
 131 
  132 
 133 
2. Material and Methods 134 
2.1. Materials  135 
Sodium deoxycholate, trans-ferulic acid 99%, C18:1E10  (Brij® O10) were all obtained 136 
from Sigma-Aldrich (Dorset, UK); Glyceryl trioleate and glyceryl tricaprate were 137 
obtained from ABITECH Corporation (Janesville, USA); Curcumin (95% from 138 
turmeric rhizome) was obtained from LKT Laboratories (Minnesota, 55130 USA). All 139 
the chemicals were used as received.  Curcumin was protected from 140 
photodegradation using aluminium foil and amber bottles and stored in dark 141 
conditions.  142 
 143 
2.2. Pseudo-ternary phase diagrams and phase inversion temperature 144 
determination  145 
The samples were prepared using glyceryl trioleate or glyceryl tricaprate, surfactant 146 
combinations of sodium deoxycholate and/or Brij® O10 and deionised water as the 147 
aqueous phase. Different surfactant ratios were explored for all surfactants, of Brij® 148 
O10 to sodium deoxycholate of 1:1, 7:3 and 9:1. The oil was added at a weight ratio 149 
range between 1-25% w/w and surfactant at a range of 1-24% w/w.  Systems were 150 
classified as a microemulsion, nanoemulsions, emulsion, gel or two-phase system. 151 
Pseudo ternary phase diagrams were then generated using XL STAT. This allowed 152 
the microemulsion region to be identified and separated from other forms 153 
(emulsions, two phase systems, gels or nanoemulsions) in order to perform further 154 
analysis.  All formulations were made up to 2 g by mixing the oil with deionised 155 
water, sodium deoxycholate, and Brij® O10. Mixtures containing Brij® O10 were 156 
stirred using a magnetic stirrer (Stuart US152 Hot Plate & Stirrer, UK) in a water bath 157 
set at a temperature between 70-75 qC for 10-15 minutes. They were then vigorously 158 
stirred until reaching room temperature (22 qC ± 2 qC).  All samples were monitored 159 
regularly for signs of phase separation for a total period of one month. Based upon 160 
appearance, samples were categorized as isotropic ϕi or milky/cloudy ϕm.  161 
 162 
2.3. Preparation of curcumin eutectic mixtures 163 
Eutectic mixtures were made based on variable stoichiometric ratios.  The eutectic 164 
mixtures were produced using neat solid-state grinding for 15 minutes and 165 
mechanochemical activation using a ball mill (Retsch) with frequency of 25 Hz and 166 
milling time of 10 minutes. The mixtures were co-ground, then placed in a grinding 167 
jar with a grinding ball using the same stoichiometric ratios of CUR and FA.  The 168 
resultant powders were assessed using thermal analysis, FTIR and x-ray powder 169 
diffraction to confirm crystalline structure.  170 
 171 
2.4. Differential scanning calorimetry of microemulsions with eutectic mixtures 172 
Thermal analysis of the oils and liquid crystals that were made was performed using 173 
differential scanning calorimetry (DSC Q2000, TA instruments, UK). Each sample 174 
was placed in a crimped aluminium pan before being hermetically sealed. A typical 175 
thermogram was obtained by initially allowing the sample to equilibrate at -50 qC for 176 
5 minutes. Samples were then heated up to 50 qC at a heating rate of 10 qC/min. All 177 
samples were purged with nitrogen gas flowing at 50 mL/min. The thermograms that 178 
were produced were then analysed to find the melting points and enthalpy values 179 
using Universal Analysis 2000 (TA instruments).  All samples were repeated in 180 
triplicate.   181 
 182 
2.5. Solubility measurements of curcumin 183 
CUR and CUR/FA eutectic mixtures were individually added to 1 mL of 184 
microemulsion of desired composition. The samples were then mixed on a rotary 185 
mixer for a total period of 72 hours whilst covered with aluminium foil to protect from 186 
light. Samples were centrifuged for 5 minutes (Sanyo MSE Micro Centaur, UK) at 187 
13,000 rpm to remove undissolved curcumin. 100 PL of each supernatant was then 188 
removed and diluted up to 10 mL with propan-2-ol. A UV-vis measurement of the 189 
diluted supernatant was carried out at wavelength of 429 nm.  190 
  191 
 192 
2.6. Stability studies using photospectroscopy 193 
1 g of each microemulsion was diluted by a factor of 5 using phosphate buffer (pH 194 
7.5), and then 1 mL was transferred to three separate centrifuge tubes that 195 
contained CUR or eutectic mixtures. All the tubes with samples were placed onto a 196 
rotary mixer with fixed mixing speed for 24 hours and light protected using aluminum 197 
foil. Samples were then centrifuged for 5 minutes at 13,000 rpm (Sanyo MSE Micro 198 
Centaur, UK). 100 µL of the supernatant was taken and diluted to 25 mL with 199 
propan-2-ol. Absorbance was determined at a wavelength of 429 nm using Varian 200 
Cary Bio (Agilent, USA). Absorbance of the same sample was re-measured over 21 201 
days to study overall stability.  Degradation experiments were carried out via adding 202 
30 µL of the CUR solution (methanol) to 3 mL of buffer (pH 7.5) in order to maintain 203 
the CUR concentration difference between initial concentration of 4 mM to final 204 
concentration of 40 µM.   205 
 206 
2.7. 1H and 13C NMR studies  207 
1H NMR spectra were recorded on a Bruker Avance III spectrometer (Bruker, 208 
Germany) operating at Larmor frequency of 500 MHz (11.75T) using standard 209 
Bruker zg30 and noesypr1d pulse sequences. 1D NOESY allowed presaturation of 210 
the water signal during the relaxation delay (RD) which improved signal-to-noise 211 
ratio of the spectra. The 90° pulse was 10.8 μs at the power level of 17.22 W. The 212 
mixing time (tm) was set to 0.05 s. Between 32 and 64 transients were recorded with 213 
relaxation delay of 1 and 2 s respectively for zg30 and noesypr1d and averaged into 214 
each spectrum. All spectra were referenced using TSP signal at 0 ppm.  215 
The temperature of the sample was changed in the range between 297 and 327 K in 216 
5 K steps and controlled with +/- 1 K error. Once desired temperature was reached 217 
each temperature point was equilibrated for 10 min before acquiring the spectrum.    218 
The confirmatory 2D HMBC spectrum was recorded on the 500 MHz spectrometer 219 
with 1H parameters optimised as above and the 13C parameters as follows: Larmor 220 
frequency of 125.78 MHz; the 90° pulse was 8.25 μs at the power level of 99.61 W. 221 
The spectral widths were 2000 Hz and 15092.9 Hz in the direct and indirect 222 
dimensions respectively. 2048 and 256 FID points were recorded in the direct and 223 
indirect dimension, respectively. 256 single transients were averaged into each of 224 
the indirect dimension’s points.    225 
 226 
2.8. LC-MS studies   227 
The analysis was performed using a Thermo Accela HPLC connected to an LTQ-228 
Orbitrap XL (Thermo Fisher Scientific Inc., San Jose, CA). Chromatographic 229 
separations were carried out by means of a Thermo Hypersil Gold 50 x 2.1 mm C18, 230 
pore size 175Å, particle size 1.9 µM column maintained at 30 °C and a methanol 231 
mobile phase. 2 µL was injected of circa 50 µg/mL samples that had been made up 232 
in methanol. The gradient was isocratic with a flow rate of 200 µL/min.  The LC-MS 233 
was performed with a run time of 10 min. Positive ion mode was employed with ions 234 
being directed into the Orbitrap detector scanning in the range 80 – 2000 m/z. 235 
Resolution was set at 15k and phthalate (413.266230) was used as a lock-mass.  236 
Thermo Xcalibur software was used both for acquisition and for data analysis. 237 
Extracted ion chromatograms were generated for the protonated and sodiated 238 
species of CUR and FA. These were 369.1333, 391.1152 and 195.0652, 217.0471, 239 
respectively. Mass tolerance was set at 5 ppm and smoothing, and baseline 240 
subtraction was applied. 241 
 242 
2.9. Dynamic Light Scattering (DLS) and zeta potential measurements 243 
Samples were diluted to 1 mL with ultra-pure water and transferred to a glass 244 
cuvette and analyzed using a Zetasizer (Malvern Zetasizer nano series, UK). The 245 
refractive index and viscosity of distilled water were used as reference values.  A 246 
series of dilutions were made to ensure consistent scattering and to avoid multiple 247 
scattering. The temperature was set at 25 °C. Each sample was allowed to 248 
equilibrate for 60 seconds and a total of 12 runs per measurement were used with 10 249 
seconds per run. Z-average diameter in nm obtained represented the particle/ 250 
droplet size of the samples.  251 
 252 
2.10. X-ray powder diffraction measurements 253 
The polymorphic nature of the formed samples was studies using x-ray powder 254 
diffraction (XRPD).  All samples were scanned using a Bruker D8 advance X-ray 255 
diffractometer (Bruker AXS GmbH, Germany) which is a Cu-source, theta– theta 256 
diffractometer equipped with a Lynx eye position sensitive detector. It was operated 257 
at 40 kV generator voltage and 40 mA generator current. The samples were 258 
analysed using DFFRAC plus XRD commander software (Bruker AXS GmbH, 259 
Germany) with a 2θ range of 5-45°, a step size of 0.02°and time per step of 1.33s.    260 
 261 
2.11. Cryogenic-Scanning Electron Microscopy (Cryo-SEM) 262 
A cryo-SEM was used to visualise the samples in a frozen hydrated state. A rivet 263 
was fitted to a cryo stub and a small amount of the samples were deposited onto the 264 
rivet and another rivet was placed on top. The cryo stub was secured to a specimen 265 
shuttle which was plunged into nitrogen slush at −210°C and transferred under 266 
vacuum to the Quorum PP2000T cryo-SEM preparation chamber (Quorum 267 
Technologies Ltd, United Kingdom) at -190oC. The sample was then sublimed at -268 
90oC for 15 minutes. The temperature of the preparation chamber was then lowered 269 
to -135oC and the sample was sputter coated with a thin layer of platinum for 80 270 
seconds at 9 -10mA. The sample was transferred to the FEI Quanta 600 FEG 271 
scanning electron microscope (FEI, Eindhoven, Neverlands) in high vacuum mode at 272 
-135oC and the images were recorded at an accelerating voltage of 20 kV. 273 
 274 
2.12. Cultivation of U251 Cells 275 
Human glioblastoma cell line U251 (Cell Line Service, Eppelheim, Germany) were 276 
cultivated in Dulbecco’s Modified Eagle’s Medium (DMEM)-High glucose (Sigma-277 
Aldrich, Gillingham, United Kingdom) supplemented with 1% L-glutamine (200 mM, 278 
Sigma-Aldrich) and 10% heat-inactivated fetal bovine serum (Sigma-Aldrich, 279 
Gillingham, United Kingdom). Human glioblastoma cell line U251-NF-κB-GFP-LUC 280 
reporter cells were generated previously [25] and were cultivated in normal 281 
cultivation media supplemented with 5 µg/mL puromycin (Apollo Scientific, 282 
Stockport, U.K.). All cells were maintained in a humidified incubator at 37°C and 5% 283 
(v:v) CO2. Early passage U251 cells (passage 3-20) were used for all experiments. 284 
U251 cells are well established model cells that are used for drug screen and signal 285 
transduction research in cancer cells [26-28]. Importantly, this cell line is also widely 286 
used to study the impact of curcumin on cancer cells including studying of pro- and 287 
anti-inflammatory signal transduction pathways [29-31]. In this context, NF-kappaB is 288 
not crucially involved in regulation of inflammation but also regulates cancer cell 289 
proliferation and migration and plays a pivotal role in drug resistance [32, 33].  290 
Therefore, assessing NF-kappaB activity in U251 cells represents a widely used and 291 
state-of-the-art approach to study the impact of anti-inflammatory drugs on various 292 
cancer cells. 293 
 294 
2.13. Cell Viability Assay 295 
Cell viability assays were performed using the Cell Proliferation Kit II (Sigma-Aldrich) 296 
according to manufacturer’s recommendations. Briefly, 5x103 U251 cells per well 297 
were seeded in 96-well plates for 24 hours to reach 50% confluency. Subsequently, 298 
the medium was changed to the cultivation medium with the respective treatment 299 
and XTT assay was performed after 48 hours of incubation. Absorbance was 300 
measured using Spectra Max iD3 plate reader (Molecular Devices, Wokingham, 301 
United Kingdom) at an excitation wavelength of 490 nm and a reference wavelength 302 
of 650 nm.  303 
 304 
2.14. Luciferase Assay 305 
U251-NFκB-GFP-LUC cells were seeded in 24-well plates in normal cultivation 306 
medium prior to two hours starvation in FBS-free medium and subsequently exposed 307 
to 10 µM of the respective curcumin formulation, 10 ng/mL tumour necrosis factor-308 
alpha (TNF-α, (PeproTech), TNF-α /curcumin, ultrapure E. coli-derived 309 
lipopolysaccharide (LPS, Escherichia coli K12, InvivoGen) 1 µg/mL LPS, LPS / 310 
curcumin, TNF-α /Bay-11-7082, or LPS/Bay-11-7082, respectively.  311 
Cells were lysed after 48 hours of incubation and the luciferase bioluminescence 312 
was assessed using the Luciferase Assay System (Promega, Southampton, United 313 
Kingdom) and a Spectra Max iD3 plate reader.  314 
 315 
2.15. Statistical analysis 316 
GraphPad Prism 5 was used to perform statistical analysis. Student’s t-test (two-317 
tailed, 95% confidence interval) or one-way ANOVA with Bonferroni’s Multiple 318 
Comparison Test (95% confidence interval) was applied, where appropriate. Data 319 
from at least three independent experiments was collected and P value< 0.05 was 320 
considered as significant.  321 
 322 
3. Results and discussion 323 
3.1. Formation regions of microemulsions based on pseudo-ternary phase 324 
diagrams and particle/ droplet size analysis  325 
Formation of small droplets in the dispersed phase is associated with a large 326 
reduction of surface tension and therefore stable microemulsions are formed [34].  327 
Depending on the composition of surfactants, other less stable intermediate 328 
structures such as emulsions nanoemulsions can also form.  The distinction between 329 
the different structures was made based on visual inspection and droplets/particles 330 
size measurements .  To form the microemulsions, three ratios of Brij® O10 to 331 
sodium deoxycholate (SD) were prepared, namely 1:1, 7:3 and 9:1.  In addition, 332 
microemulsions were formed using Brij® O10 alone.  These ratios were guided by 333 
preliminary studies where it was not possible to form emulsions or microemulsions 334 
using molar ratios Brij® O10 to SD below 1:1. Likewise, it was not possible to form 335 
microemulsions when sodium deoxycholate was used as the sole surfactant.  336 
 337 
Pseudo-ternary phase diagrams were used to map the area of existence for 338 
amphiphilic association structures (i.e. emulsion, microemulsion, nanoemulsion).  339 
The area of existence was divided into isotropic, transparent or opalescent samples 340 
(ϕi) and cloudy/milky samples (ϕm).  Samples that were in the ϕi region were 341 
microemulsions or nanoemulsions while samples that were in the ϕm region were 342 
considered emulsions. Results showed that samples prepared using Brij® O10 with 343 
either solid-based glyceryl tricaprate or liquid-based glyceryl trioleate lead to 344 
formation of microemulsions (Figure 2). The general trend showed that the solid oil 345 
formed more microemulsions when compared with the liquid oil.  The use of Brij® 346 
O10 has generated more microemulsions while when Brij® O10 was mixed with SD, 347 
the number of formed microemulsions was lowered.  This trend could be clearly seen 348 
when using ratios of Brij® O10:SD <9:1 as at these ratios only emulsions were 349 
formed.  At a molar ratio of Brij® O10:SD of 9:1, a mixture of emulsions, 350 
nanoemulsions and microemulsions was formed.   351 
  352 
Particle/droplet size analysis of microemulsions showed similar trends to those 353 
observed in the pseudo-ternary phase diagrams (Figure 3).  As can be seen, the size 354 
of the microemulsions droplets increased with reducing the surfactant ratio with the 355 
size varied from 12.0 ± 0.04 nm to 23.9 ± 0.1 nm, in proportion to reduced ratio of 356 
Brij® O10 from 24% to 15% and increased ratio of oil from 5% to 10%.  The smallest 357 
particle/ droplet size was found for samples prepared using 5% glyceryl tricaprate 358 
(solid oil) and 24% Brij® O10 (12.0 ± 0.036 nm) which was statistically similar to the 359 
size of microemulsions droplets formed using 5% glyceryl trioleate (liquid oil) and 360 
24% Brij® O10 (12.4 ± 0.148 nm) (p<0.05).  Overall, a statistical difference in 361 
particle/ droplet size was found between microemulsions formed from the solid oil 362 
when compared with microemulsions formed form the liquid oil (Figure 3).  The 363 
statistical analysis was based on one-way analysis of variance (ANOVA) (p-value 364 
<0.05) (Figure 3).  This aligns with the above findings that showed that the solid oil 365 
formed more microemulsions compared to the liquid oil (Figure 2). The zeta potential 366 
measurements showed that the particles/ droplets exhibited negative values (Figure 367 
3) with values increasing in proportion to the surfactant’s ratio (-63 to -50 mv).   368 
These values agreed with previously reported values for Brij® O10 emulsions [35]. 369 
The relatively high zeta potential values can have dramatic impact on the physical 370 
stability of the formed microemulsions.  The resulting repulsion due to the associated 371 
surface charges can be detrimental for maintaining the droplets/ particles segregated 372 
and prevent possible aggregation and phase separation.   373 
 374 
3.2. Incorporation of CUR and CUR-FA eutectic mixtures  375 
The CUR/FA eutectic mixtures were prepared using mechanochemical activation 376 
using different stochiometric ratios (1:1, 1:2, 1:3).  Formation of the eutectic mixtures 377 
was confirmed using thermal analysis and XRPD (Figure 4). CUR:FA (1:1) showed a 378 
single melting point indicating the formation of single phase, hence this composition 379 
was used throughout this study.  The other ratios (1:2 and 1:3) showed a shoulder 380 
indicating that the mixtures contained eutectic mixtures in addition to pure 381 
components. Lack of exothermic recrystallization peak suggests that the formed 382 
structures are eutectic mixtures rather than corresponding co-crystals [21, 36]. 383 
Confirmation of formation of eutectic mixture was further confirmed using x-ray 384 
powder diffraction by which no new peaks were detected in agreement with thermal 385 
analysis results (Figure 4).     386 
CUR/FA eutectic mixtures were incorporated into the microemulsions and the final 387 
particles/ droplet were assessed using thermal analysis, particle/ droplet size and 388 
solubility measurements. As can be seen in Figure 5, the melting peak onset of the 389 
solid oil (glyceryl tricaprate) was observed at around 29 qC while the sharp melting 390 
endotherm at 0qC refers to melting of ice and the melting at -20qC refers to melting 391 
of the surfactant Brij® O10.   The corresponding microemulsion showed slightly 392 
lower melting of the oil at around 25 qC (marked with number 1 in Figure 5) which 393 
indicates that the oil phase was solid/semi solid at room temperature.  This is 394 
important finding as it indicates that the drug or eutectic mixtures are entrapped 395 
inside solid nanoparticles rather than liquid droplets which can have significant 396 
impact on stability.  When CUR was incorporated into the microemulsion, the melting 397 
peak of the oil can still be seen at 25 qC.  It is interesting to observe that when the 398 
eutectic mixture was incorporated into the microemulsion, a new endothermic peak 399 
could be observed at 13 qC.   We anticipate that the CUR containing microemulsion 400 
is partially solid at room temperature while the CUR/FA is predominately liquid (or 401 
highly viscous liquid).  Similar observation was reported before by which the drug 402 
can exist inside solid droplets of nanoemulsions/ microemulsions [37]. 403 
The liquid oil showed a melting peak onset at around -20 qC preceded by 404 
recrystallization peak at -28 qC. It was not possible to observe a melting peak of the 405 
liquid oil when CUR or CUR/FA were incorporated.  This behavior often reflects 406 
favorable interactions preventing recrystallization and associated melt.  The 407 
thermogram of the liquid oil microemulsions showed the lack of an endotherm 408 
indicating that the oil phase was completely in the liquid state.  It is expected that at 409 
room temperature, the kinetic energy would have been sufficient to weaken any 410 
intermolecular interactions.  It is anticipated that the impact of thermal events 411 
happening in the solid oil will have greater impact than the liquid oil on the 412 
physicochemical properties of CUR and CUR/FA.  As mentioned above, it was 413 
possible to observe the endothermic peak associated with the melt of the solid oil at 414 
approximately 25°C.  This was shifted to 13°C upon the addition of the CUR/FA 415 
eutectic mixtures.  Such change indicates structural changes and potentially 416 
interactions between the oil and CUR/FA.   More importantly, a solid core could limit 417 
mobility and enhance stability. Similar trend was observed before for solid lipid 418 
nanoparticles with melting endotherms reflected in different solubility of the drug [37].   419 
 420 
As was seen above, the melting endotherm for the oil seemed to change when either 421 
CUR or CUR/FA were added.  In order to understand the reason for this 422 
phenomenon, it became important to study CUR-oil and CUR/FA-oil 423 
thermodynamics of mixing.  To achieve this, CUR or CUR/FA were dissolved into the 424 
solid oil and thermal events were then characterized.  As can be seen in Figure 6, 425 
the melting peak onset of CUR/FA can be seen at 149 °C. The melting endotherms 426 
of the pure CUR and pure FA can be seen at 177.6 and 173 °C, respectively.  Once 427 
the oil melted, it did not show any endothermic peaks that could indicate evaporation 428 
or degradation within measured temperature range.  There was a single endothermic 429 
peak at around 140 °C which is significantly lower than the melting endotherm of the 430 
CUR/FA.  We anticipate that this is the eutectic CUR/FA however this may 431 
correspond to co-crystals formation. Examination of the XRPD peaks were not 432 
conclusive as because of the low intensity of CUR/FA compared to the oil. 433 
Nevertheless, observing the CUR/FA peak within the oil signifies that the CUR/FA 434 
mixture maintained its crystalline structure inside the oil phase instead of separating 435 
as separate FA or CUR crystals.   The fact that microemulsions remained visually 436 
clear, suggest that CUR/FA existed as nanocrystals inside the oil particles/ droplets. 437 
The solid oil melted at 25° showing two polymorphic transitions at 11°C and -7°C 438 
which were not affected by incorporation of CUR or CUR/FA eutectic mixtures.  The 439 
cooling rate was controlled at 10 °C/min while a fast cooling cycle was used for 440 
microemulsions to avoid structural changes in the microemulsion system.  Hence, 441 
these polymorphic changes were not seen in Figure 5.   442 
 443 
Incorporation of the CUR or CUR/FA eutectic mixtures resulted in changes in 444 
particle/ droplet size of the microemulsions.  Particle/ droplet size of microemulsions 445 
incorporating CUR or with CUR/FA was statistically different (p<0.05) to 446 
microemulsions (Figure 7).  As shown above, using a combination of SD and Brij® 447 
O10 resulted in lower number of formed microemulsions than when using Brij® O10.  448 
Upon incorporation of CUR or CUR/FA, the particle size has grown to a larger extent 449 
in microemulsions prepared using the surfactants mixture than Brij® O10.  This trend 450 
was more noticeable when the liquid oil was used to from the microemulsions 451 
resulting in approximate difference of 10nm.  It is interesting to observe that there 452 
was a minimum impact of CUR/FA inclusion on the microemulsions prepared using 453 
the solid oil.  In fact, when the mixture of SD and Brij® O10 was used, the size of the 454 
microemulsions particles/ droplets decreased by 2-3 nm.   These results mirror the 455 
thermal analysis findings observed above by which the solid oil based 456 
microemulsions maintained smaller particle/ droplet size than the liquid oil based 457 
microemulsions.  Existence of the CUR or CUR/FA as solid entities within the 458 
physically stable droplets can prevent CUR degradation and precipitation when 459 
exposed to aqueous environment.  Cryo- SEM was used to examine the structure of 460 
the microemulsions to assess if the increased size was due to aggregation of the 461 
formed particles.  As can be seen in Figure 7, formed microemulsions maintained 462 
their segregated structures with uniform size distribution. The continuous globular 463 
structures represent frozen oil droplets enwrapped within the Brij® O10 network.  464 
These results support the thermal analysis findings in that CUR as well as CUR/FA 465 
existed as nanocrystals inside the oil phase and in equilibrium with dissolved 466 
CUR/FA.  467 
 468 
 469 
3.3. Enhanced solubility of curcumin in Brij® O10/SD microemulsions  470 
As shown in Figure 8, microemulsions showed significantly higher (p<0.05) solubility 471 
of CUR alone when compared to CUR/FA eutectic mixtures in both solid glyceryl 472 
tricaprate and liquid glyceryl trioleate based microemulsions.  For instance, the 473 
highest solubility was 5.56 ± 0.13 mg/mL for microemulsions prepared with 24% 474 
Brij® O10 and 10% glyceryl tricaprate for CUR. This was significantly higher 475 
(p<0.05) than 4.84 ± 0.08 mg/mL and 4.85 ± 0.14 mg/mL for the CUR/FA eutectic 476 
mixtures in solid and liquid oil based microemulsions, respectively. Overall, 477 
incorporation of CUR into microemulsions contributed to a solubility of CUR ranging 478 
from 3.71-5.56 mg/mL, whilst 3.14-4.89 mg/mL was the range of those with the 479 
addition of CUR/FA eutectic mixtures.  The reduced solubility of CUR when the 480 
CUR/FA was added suggests that FA is localized within the oil phase leading to 481 
lower solubility of CUR.  If FA was dissolved within the continuous aqueous phase, 482 
then a reduction in solubility of CUR would not be affected.  This additional 483 
occupancy of FA lead to increased size of microemulsion particles/ droplet as 484 
observed above.  The aqueous solubility of CUR was found to be 0.16 µg/mL while 485 
the solubility of CUR from the eutectic mixture was 0.06 µg /mL µg which suggests 486 
that CUR/FA eutectic mixtures were present as practically insoluble nanocrystals.    487 
  488 
Interestingly, referring to Figure 9, microemulsions prepared using Brij® O10 as the 489 
only surfactant showed greater solubility of CUR when compared with the mixture of 490 
Brij® O10 and sodium deoxycholate in both solid and liquid oil based 491 
microemulsions. For example, with the combination of 24% surfactant and 5% oil, 492 
sample prepared with single surfactant had a solubility of 5.32 ± 0.14 mg/mL which 493 
was significantly higher (p<0.05) than that of 3.90 ± 0.1 mg/mL with surfactant 494 
mixture using glyceryl tricaprate as the oil; whilst solubility of 5.39 ± 0.12 mg/mL and 495 
3.83 ± 0.27 mg/mL were obtained for microemulsion prepared using glyceryl trioleate 496 
with single surfactant and surfactant mixture, respectively. However, the differences 497 
in CUR solubility between the glyceryl tricaprate (solid based) and glyceryl trioleate 498 
(liquid based) oils was not significant (p>0.05), irrespective of the use of single 499 
surfactant or surfactant mixture.   The lower solubility of CUR in the SD containing 500 
microemulsions suggest unfavorable head groups interaction with Brij® O10 causing 501 
CUR to localize deeper inside the oil droplets.  The core of the microemulsion 502 
droplets comprises entirely of the oil enclosed by the oleyl hydrocarbons of the 503 
surfactant molecules and lastly by a mantle of ethylene oxide chains, leading to 504 
enhancement in hydration as the distance from the core increases [38]. Solubility of 505 
CUR was monitored regularly to ensure that CUR remained physically stable. The 506 
samples were stored at room temperature and dark conditions as CUR can undergo 507 
photodegradation  [39]. The data in Figure 9 show that CUR had similar solubility in 508 
all samples prepared after 21 days of preparation.  There was no statistical 509 
difference (p<0.05) in solubility of CUR in freshly prepared samples and samples 510 
that were prepared 21 days after solubility measurement.  Hence, prepared 511 
microemulsions were physically stable; chemical degradation can still occur 512 
therefore it was investigated as shown below.   513 
  514 
3.4. Assessment of CUR degradation using photospectroscopy, mass 515 
spectrometry and temperature controlled 1H NMR 516 
While solubility enhancement of CUR was previously reported [40, 41], our study 517 
provides a detailed analysis of the stability of CUR while being dissolved in the oil 518 
phase as well as after being released from the vehicles.  It has been reported before 519 
that a possible degradation pathway for CUR is autoxidation and solvolysis [10, 42].  520 
To simulate these degradation conditions, phosphate buffer mixed with methanol 521 
was used for diluting the samples while CUR concentration was checked at regular 522 
intervals for a total duration of 24 hours.   UV spectrophotometer was used to 523 
monitor CUR peak at wavelength of 429 nm.  Within this region there are no 524 
overlapping peaks with degradation products nor from FA.  Measurements were 525 
performed at room temperature and 37°C using phosphate buffer to dilute the 526 
samples.  As can be seen in Figure 10, CUR degraded within 20 minutes to less 527 
than 50% of its original concentration.  Autoxidation has been shown to be major 528 
pathway for CUR via phenoxy free radical formation and propagation through 529 
interaction with molecular oxygen [10, 43]. In order to minimize autoxidation when 530 
dissolving CUR into the phosphate buffer, degassing was used to remove dissolved 531 
oxygen before adding CUR to the buffer. As can be seen, initial rate of CUR 532 
degradation was slowed, however faster degradation kinetics occurred after 15 533 
minutes.  These results confirm that the presence of oxygen accelerated the 534 
degradation of CUR.  Furthermore, addition of DMSO to the phosphate buffer 535 
showed slower degradation kinetics which is likely because the organic solvent 536 
reduces the amount of free •OH.  Interestingly, dissolving CUR and FA slowed down 537 
degradation in a similar pattern to inclusion of DMSO (Figure 10).  This confirms the 538 
suggestion that FA can scavenge free •OH which initiate the autoxidation process.  539 
Inclusion of FA did not completely stop the process which could be attributed to 540 




To simulate degradation at ambient conditions, degradation of CUR was studied at 545 
room temperature. As can be seen in Figure 11, initial steady reduction in CUR was 546 
observed in all samples (microemulsions and pure CUR).   Liquid oil based 547 
microemulsions showed a similar trend to solid oil based microemulsions, but CUR 548 
degraded at a faster rate in liquid oil based microemulsions.  There was a positive 549 
impact for the inclusion of FA reflected by higher amount of remaining CUR, where 550 
the range of percentage remaining was 70.20 ± 0.70 - 83.26 ± 1.24% when CUR/FA 551 
eutectic mixtures were incorporated. This is in contrast to 55.42 ± 0.82% - 77.05 ± 552 
0.76% when CUR alone was added to the microemulsions.  Overall, 17% - 45% of 553 
incorporated CUR degraded after exposure to phosphate buffer at pH 7.5, while the 554 
percentage of degradation of CUR without incorporation was 63%, indicating that 555 
incorporating CUR into microemulsions significantly improved the chemical stability 556 
of CUR (p<0.05). Solid oil based microemulsions prepared using Brij® O10 557 
embedding CUR/FA eutectic mixtures showed best stability of CUR.  This could be 558 
seen as 37.48 ± 2.48% of CUR alone remained while the microemulsions 559 
embedding the eutectic mixtures had significantly higher percentage (p<0.05) of 560 
83.26 ± 1.24%, showing a marked difference of 45.78%.   561 
The mixture of Brij® O10 and SD showed improved stability of CUR in both liquid 562 
and solid oils when CUR/FA eutectic mixtures were used. Similar effect was seen for 563 
Brij® O10 and SD mixture with CUR/FA.  SD has been recently used as a reducing 564 
agent with oxidation happening at the hydroxyl groups to form carbonyl groups [44].  565 
This oxidation process was UV induced hence it may contribute to further 566 
stabilisation of CUR against photodegradation.   This effect was reversed when CUR 567 
was incorporated into the microemulsions which we speculate that could be due to 568 
induction of alkaline hydrolysis which seemed to be prevented in the presence of 569 
partially ionised FA. 570 
 571 
Mass spectrometry was used to monitor CUR peak using pure water as solvent and 572 
compared with methanol CUR solution. As can be seen (Figure 10), CUR peak was 573 
detected as 369.1333 and 391.1152 and for FA the peaks were 195.0652 and 574 
217.0471 (protonated and sodiated species, respectively).  It was possible to detect 575 
CUR peak in microemulsions with approximate intensity to the CUR peak with the 576 
FA eutectic mixtures.  The FA peak can also be seen indicating no change in its 577 
intensity over time.  The focus of this study is the possible conversion of CUR to FA, 578 
but our findings showed that CUR does not degrade into FA.  While FA could be a 579 
minor degradation product [45], its presence improved stability of CUR possibly via 580 
scavenging free radicals, which were identified as possible mechanism for CUR 581 
degradation [19].   582 
As shown above, degradation rate happened significantly faster at 37 °C compared 583 
to ambient temperature (20-22°C).  Heating has been shown to accelerate 584 
degradation of CUR to happen within less than ten minutes [42].  To simulate the 585 
impact of temperature on degradation, the thermal stability of CUR was assessed 586 
using temperature controlled 1H NMR experiment in the biologically relevant 587 
temperature range of 297 K to 327 K (24 to 54°C).  CUR in methanol-d4 is present 588 
as CUR and demethoxycurcumin in equilibrating keto-enol tautomers. There was 589 
clear evidence of that in the HMBC spectrum (data not shown) which agreed with 590 
previously published studies [46]. The comparison of 1H spectra in Figure 12 (a) and 591 
(b) shows that between 6.4 and 7.8 ppm the observed signals originate 592 
predominantly from CUR, not from either the oil or surfactant used. The 593 
characteristic pattern of CUR signals in methanol-d4 is repeated for CUR in 594 
oil/surfactant/D2O. However, the chemical shifts, as well as widths of most peaks 595 
were affected by the change in neighboring environment, which is likely to be caused 596 
by the difference in the solvent.  The 1H spectra in Figure 12 (c) shows CUR signals 597 
recorded between 297 and 327 K. No significant changes have been observed (only 598 
typical temperature shifts) suggesting that the CUR remains stable within this 599 
temperature range.  Overall, these results confirm findings obtained above showing 600 
that CUR did not degrade to FA at least within short time scale and it remained 601 
stable when formulated into the microemulsions.  The results do not confirm whether 602 
autoxidation is happening and whether bicyclopentadione as major degradation 603 
product is formed, however these results confirm that increasing temperature did not 604 
lead to FA formation.  A previous study has shown that CUR undergoes thermal 605 
degradation leading to the formation of FA as a major degradation product [47].  606 
Hence, our results suggest that CUR resisted this degradation possibly through 607 
physical complexation with FA. 608 
 609 
3.5. CUR shows increased anti-inflammatory potential  610 
Visual inspection of microemulsions after storage for 12 months showed that glyceryl 611 
trioleate (liquid oil) based microemulsions vanished when compared with glyceryl 612 
tricaprate (solid oil) based microemulsions (Figure 13).  The color intensity of CUR 613 
was retained in both solid and liquid oil based microemulsions that contained 614 
CUR/FA eutectic mixture signifying the positive effect of including FA in the 615 
microemulsions.  It is becoming clear that the use of FA to extend the stability of 616 
CUR is a successful approach.  Incorporation into microemulsions has significantly 617 
enhanced CUR solubility to approximately 5 mg/mL compared to aqueous solubility 618 
of 60 ng/mL.  The remaining question whether the combination of CUR and FA had 619 
any impact on anti-inflammatory potential.  In order to validate that the decrease of 620 
NF-kappaB signal caused by the CUR formulations is a result of their anti-621 
inflammatory activity and not caused by reduced cell viability, XTT assays were 622 
performed. U251Cells were exposed to increasing concentrations of CUR followed 623 
by measuring the XTT absorbance. Analysis of the data showed no negative impact 624 
on cell viability (Supplementary data) at the concentrations used for the assessment 625 
of NF-kappaB activity (10µM). To assess the anti-inflammatory potential of freshly 626 
prepared curcumin formulations, a previously developed U251-NF-κB-GFP-LUC 627 
reporter system was used [25]. In order to simulate inflammation in vitro and to 628 
assess the anti-inflammatory potential of the different CUR formulations, reporter 629 
cells were exposed to the well characterised pro-inflammatory molecules TNF-α, or 630 
LPS or combinations of CUR formulations with TNF-α or LPS. As an additional 631 
control, the broad spectrum anti-inflammatory inhibitor Bay-11-7082 was used [48]. A 632 
significant up-regulation of the NF-κB-dependent luciferase bioluminescence was 633 
observed in both cells exposed to TNF-α and LPS (Figure 13). Notably, all new CUR 634 
formulations showed stronger anti-inflammatory action for both stimuli.   The effect 635 
was three-fold stronger than CUR dissolved in DMSO. The difference among the 636 
studied microemulsions was insignificant signifying that CUR had similar activity in 637 
all microemulsions. However, CUR/FA containing formulations contained ratio of 1:1 638 
hence the effect of CUR was significantly augmented in CUR/FA microemulsions 639 
and estimated to be two folds stronger anti-inflammatory potential compared to CUR 640 
microemulsions.      641 
 642 
4. Conclusions  643 
In summary, microemulsions incorporating curcumin and ferulic acid showed 644 
improved solubility, stability as well as improved blockage of the cytokine, TNF-α.  645 
The solubility enhancement was significantly higher than previously reported 646 
methods such as incorporation into micellar solutions [49], use of solubilizers [50] 647 
and microencapsulation in whey protein isolate [51].  This represents a novel 648 
approach to maintain curcumin in its native form and prevent its possible 649 
degradation. Assessment of oil droplets size revealed a narrow and consistent size 650 
distribution which was affected by the presence of curcumin /ferulic acid.  The 651 
physical nature of the oil used to prepare the microemulsions had a significant 652 
impact on stability as was reflected by solid glyceryl tricaprate based microemulsions 653 
compared to the liquid glyceryl trioleate microemulsions.   This was attributed to the 654 
presence of curcumin /ferulic acid nanocrystals that were shown to exist in the solid 655 
oil as indicated by thermal analysis results.  NMR and LC-MS studies confirmed that 656 
curcumin did not convert into ferulic acid even when exposed to higher 657 
temperatures.  Overall, these results present a novel solution to overcome poor 658 
absorption associated with the use of curcumin.    659 
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Captions to Figures  
 
Figure 1: Schematic showing the composition of formed microemulsions 
encapsulating CUR/FA eutectic mixtures and stabilised by Brij® O10/sodium 
deoxycholate or Brij® O10 only.  
 
Figure 2:  Pseudo-ternary phase diagrams of glyceryl tricaprate (a), (b), (c), (d) and 
glyceryl trioleate (e), (f), (g), (h) with Brij® O10 and sodium deoxycholate (SD) as the 
surfactants system.  Colours indicate formed structures as microemulsions (red), 
nanoemulsions (yellow), emulsions (blue) and two phases/gels (grey). Data are 
means + SD of at least three experiments (n=3).  
 
Figure 3: Particle size analysis of microemulsions formed from solid and liquid oils 
using Brij® O10 (B) and oil (O); the symbols (*), (**), (***), (+) indicate no statistical 
difference among annotated groups, the rest of data sets are statistically different 
(p<0.05) and zeta potential measurements of microemulsions containing various 
ratio of oil (liquid) and surfactant Brij® O10; the symbol (*) indicates a statistical 
difference while (x) indicates no statistical difference (p<0.05).  A total of 10 
measurements were collected for each sample. Data are means ± SD compared to 
measurements within the same and different data set, analysis was performed based 
on one-way analysis of variance (ANOVA), Tukey  post-hoc analysis using SPSS 
v25.   
 
Figure 4: DSC thermogram showing the melting endotherm of curcumin and ferulic 
acid and their eutectic mixtures. The XRPD scans confirm DSC results showing lack 
of new emerging peaks. All measurements were repeated in triplicate (n=3).  
  
Figure 5: DSC thermograms of curcumin or curcumin/ferulic acid in glyceryl 
tricaprate microemulsion (a) and glyceryl trioleate microemulsion (b). All 
measurements were repeated in triplicate (n=3). 
Ca i n   Fig e Click here to ie  linked References
Figure 6: DSC thermograms of CUR or CUR/FA dissolved in glyceryl tricaprate (solid 
oil) showing pure components and eutectic mixture. All measurements were repeated 
in triplicate (n=3). 
Figure 7: Particle size analysis of microemulsions with CUR or CUR/FA eutectic 
mixture (*p<0.05: microemulsions with eutectic mixtures are significantly different to 
microemulsions alone) (**p<0.05: Microemulsions with CUR are significantly different 
to microemulsions alone)  (***p<0.05: Microemulsions with CUR are significantly 
different to microemulsions alone and microemulsions with eutectic mixtures)  
(****p<0.05: Microemulsions with eutectic mixtures are significantly different to 
microemulsions alone and microemulsions with CUR). A total of 10 measurements 
were collected for each sample. The size and morphology were further verified using 
cryo-SEM of CUR/FA microemulsion showing oil particles wrapped within the 
surfactant network.  
Figure 8: solubility measurements of CUR in microemulsions prepared using Brij® 
O10 as the only surfactant.  Microemulsions were prepared using the glyceryl 
tricaprate (solid oil) and glyceryl trioleate (liquid oil). All measurements were 
repeated in triplicate (n=3). The symbols (*) or (+) indicate no statistical difference 
(p<0.05), all other data sets are statistical different (p<0.05).  Data are means ± SD 
compared to measurements within same and different data set, analysis was 
performed based on one- a  anal i  of a iance (ANOVA), T ke  o -hoc 
analysis using SPSS v25.    
 
Figure 9: Solubility of curcumin in microemulsions prepared using (a) solid oil 
glyceryl tricaprate and (b) liquid oil glyceryl trioleate.  Measurements were performed 
immediately and after 21 days of preparation. No statistical difference between 
immediate measurements and measurements made after 21 days of preparation 
(p<0.05%). All measurements were repeated in triplicate (n=3). Data are means ± 
SD compared to measurements within same and different data set, analysis was 
performed based on one-way anal i  of a iance (ANOVA), T ke  o -hoc 
analysis using SPSS v25.    
 
Figure 10: Degradation of CUR measured using UV photospectroscopy after dilution 
in DMSO and phosphate buffer (pH 7.5), degassed phosphate buffer (pH 7.5), 
phosphate buffer (pH 7.5) and CUR/FA 1:1 physical mixture in phosphate buffer (pH 
7.5). Measurements were collected at wavelength of 429nm and at 37°C. 
Concentration of CUR was 40 µM in all measurements. All measurements were 
repeated in triplicate (n=3).  
 
Figure 11: Degradation of CUR measured at wavelength of 429nm using 
photospectroscopy after exposure to methanol and phosphate buffer (pH 7.5) in 
microemulsions prepared with 5% oil and 20% surfactant compared to CUR alone 
using (a) Liquid oil glyceryl trioleate.  (b) Solid oil glyceryl tricaprate.  (*p<0.05: All 
microemulsions with the addition of either CUR or CUR/FA are significantly different 
to CUR alone without incorporation into the microemulsions). (c  f), Extracted ion 
chromatograms for CUR (top) and FA (bottom) from 7% Brij® O10, 1% solid glyceryl 
tricaprate (c), 7% Brij® O10, 1% liquid glyceryl trioleate (d), 7% Brij® O10, 1% solid 
glyceryl tricaprate CUR:FA (1:1)  (e) and 7% Brij® O10, 1% liquid glyceryl trioleate 
CUR:FA (1:1) (f).  All measurements were performed at ambient temperature.   All 
measurements were repeated at least in triplicate (n=3). Data are means ± SD 
compared to measurements within same and different data set. 
 
Figure 12: Characteristic region of 1H NMR spectrum of CUR and FA alone or loaded 
within the formed microemulsions. Comparison between spectra of intact CUR and FA 
(red box indicates characteristic resonances) is shown in (a), whereas the comparison 
between spectra of CUR and microemulsion is shown in (b). CUR spectra recorded at 
elevated temperatures are shown in (c). 
Figure 13: U251-NF- B-GFP-Luc cells were exposed to TNF-  o  LPS follo ed b  a 
subsequent assessment of NF- B-dependent luciferase activity. A) U251-NF- B-
GFP-Luc co-exposed to TNF-  and microemulsion of CUR/FA show significantly lower 
levels of NF- B ac i i  hen com a ed o cell  e o ed ei he  o TNF-  alone o  o a 
combination of TNF-  and CUR. B) Microemulsion of CUR/FA decrease the LPS-
induced activity of NF- B com a ed o LPS alone o  a combina ion of CUR and LPS. 
Da a i  e en ed a  mean anda d de ia ion f om a  lea  h ee inde enden  
experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 were considered significant 
(ANOVA with Bonferroni correction, CI 95%). C) CUR/FA microemulsions after 
storage for 12 months at ambient conditions.   All samples contained similar 
concentration of CUR and had similar color intensity when were freshly prepared.   
 
Supplementary Figure 1: U251 cells cultivated in the presence of increasing 
concentrations of CUR for 48 hours followed by XTT-based assessment of cell 
viability. Cells showed no significant difference in viability below 400µM of CUR.  B). 
U251 cells cultivated in the presence of increasing concentrations of Curcumin 1 (7% 
C18:1E10, 1% solid glyceryl tricaprate). Cells showed no significant drop in viability 
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